Acute Porphyria Drugs

Monograph

J07CA06 - Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus vaccine (DTP-IPV-Hib), there are no conceivable porphyrinogenic effects.
Chemical description
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, inactivated poliovirus (type 1,2 and 3) and Haemophilus influenzae Type b Polysaccharide (DTP-IPV-Hib)
Therapeutic characteristics
The DTP-IPV-Hib vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type B disease from the age of 2 months. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The DTP-IPV-Hib vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
Explore alternative drugs in similar therapeutic classes J07C / J07CA or go back.
References
# Citation details PMID
*Government bodies
1. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
*Summary of Product Characteristics
2. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). INFANRIX-IPV+Hib. (Last edition: 19.02. 2015).

Tradenames

Infanrix IPV + Hib · Pentavac Infanrix · Pentavac Infanrix-ipv+hib · Pentaxim Infanrix DTPa-IPV+Hib · Pentavac Infanrix-IPV + Hib vaccine · Pediacel vaccine Infanrix-Polio+Hib · Pentavac Infanrix - IPV + Hib Infanrix-ipv+hib · Pentavac Pentavac Infanrix-Polio+Hib · Pentavac Pentaxim Pentaxim Infanrix-ipv+hib · Pentaxim Infanrix · Pentaxim INFANRIX - IPV + Hib · Pediacel · Pentaxim Vaccines
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙